The world cannot rely on just a few manufacturers in wealthy nations to supply vaccines during a pandemic. We need distributed manufacturing to ensure fairness and resilience.

Analysis

Data from **WHO** and **UNICEF** confirm that during the COVID-19 pandemic, **75% of vaccines** were concentrated in just 10 countries as of mid-2021, while low-income nations received **<1% of doses**. Bottazzi’s argument aligns with **WHO’s 2021 mRNA Technology Transfer Hub** initiative, which explicitly aims to expand regional production to address supply chain vulnerabilities and inequities. Peer-reviewed studies (e.g., *Nature*, 2022) and reports from **GAVI** and **The Lancet* further validate that centralized manufacturing in wealthy nations exacerbated delays and shortages, supporting her call for distributed production.

Background

Maria Elena Bottazzi, co-developer of the **Corbevax** COVID-19 vaccine (a patent-free, protein-subunit vaccine), testified amid criticism of **vaccine nationalism**—where high-income countries hoarded doses and blocked IP waivers. Her statement echoes longstanding critiques of **global health infrastructure**, including the **2009 H1N1 pandemic**, where similar disparities occurred. The **WTO’s 2022 IP waiver debate** and **African Union’s vaccine manufacturing partnerships** (e.g., **African CDC’s 2040 plan**) reflect ongoing efforts to address these systemic gaps.

Verdict summary

Bottazzi’s claim accurately reflects global vaccine production inequities and expert consensus on the need for decentralized manufacturing during pandemics.

Sources consulted